mdg-annual-report-2013

Recommendations

Info

142 GLOSSARYTecDAXIndex of the German Stock Exchange listing the thirty major technology equities with respect to market capitalisationand order book turnoverTechnology platformTechnology which is the basis for the development of different drug candidatesTherapeutic vaccineStimulates the immune system against acute infection or an existing tumourTriple negative breast cancerMalignant breast tumours that display neither oestrogen/gestagen nor HER2 receptors on the cell surface are termed“triple negative”VVaccinesInoculants
MEDIGENE AG ANNUAL REPORT <strong>2013</strong> FINANCIAL CALENDAR/ TRADEMARKS/ IMPRINT 143FINANCIAL CALENDAR27 March 2014Annual Report 2014Press and Analyst conference call15 May 20143-Month Report 2014Press and Analyst conference call07 August 20146-Month Report 2014Press and Analyst conference call13 November 20149-Month Report 2014Press and Analyst conference callTRADEMARKSEligard®is a trademark of Tolmar Therapeutics, Inc.EndoTAG®is a trademark of Medigene AGMedigene®is a trademark of Medigene AGPolyphenon E®is a trademark of Mitsui Norin Co. Ltd.RhuDex®is a trademark of Medigene AGVeregen®is a trademark of Medigene AGThese trademarks may be held or licensed for specific countries.
Page 6 and 7:
6 Interview with the Executive Boar
Page 8 and 9:
8 KapitelT … as in TRANSACTIONSDe
Page 10 and 11:
10 KapitelT … as in THERAPEUTIC A
Page 12 and 13:
12 KapitelT … as in T cellsTechno
Page 14 and 15:
14 KapitelT … as in teamworkJoini
Page 16 and 17:
16 KapitelT … as in TRENDFinancia
Page 18 and 19:
18 pipelinepipelinemarketed drugsin
Page 20 and 21:
20productsVeregen®ProduCt Indicati
Page 22 and 23:
22productsRhuDex®Product Indikatio
Page 24 and 25:
24productsImmunotherapiesImmunother
Page 28:
28 the shareThe ShareShare price pe
Page 31 and 32:
Medigene AG Annual report 2013 Kapi
Page 34 and 35:
34 GROUP MANAGEMENT’S DISCUSSION
Page 36 and 37:
Page 38 and 39:
Page 40:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 51 and 52:
MEDIGENE AG ANNUAL REPORT 2013 GROU
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
CONTENTCONSOLIDATED FINANCIAL STATE
Page 63 and 64:
MEDIGENE AG ANNUAL REPORT 2013 CONS
Page 65 and 66:
Page 67 and 68:
Page 70 and 71:
70 NOTES TO THE CONSOLIDATED FINANC
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93: 92 NOTES TO THE CONSOLIDATED FINANC
Page 100 and 101: 100 NOTES TO THE CONSOLIDATED FINAN
Page 126 and 127: 126 AUDIT OPINIONAUDIT OPINIONWe is
Page 128 and 129: 128 RESPONSIBILITY STATEMENTRESPONS
Page 130 and 131: 130 REPORT OF THE SUPERVISORY BOARD
Page 136 and 137: 136 GLOSSARYGLOSSARYAAAVLPAdeno-ass
Page 138 and 139: 138 GLOSSARYEEBITDAEarnings before
Page 140 and 141: 140 GLOSSARYMMajor histocompatibili
Page 144: 144 FINANCIAL CALENDAR/ TRADEMARKS/
show all

mdg-annual-report-2013

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?